Peroxisome proliferator–activated receptor γ agonists: Potential use for treating chronic inflammatory diseases
- 7 March 2002
- journal article
- review article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 46 (3), 598-605
- https://doi.org/10.1002/art.10052
Abstract
No abstract availableKeywords
This publication has 66 references indexed in Scilit:
- 15‐Deoxy‐Δ12,14‐PGJ2, but not troglitazone, modulates IL‐1β effects in human chondrocytes by inhibiting NF‐κB and AP‐1 activation pathwaysFEBS Letters, 2001
- Prostaglandin J2 Inhibition of Mesangial Cell iNOS ExpressionClinical Immunology, 2001
- Feedback Control of Cyclooxygenase-2 Expression through PPARγPublished by Elsevier BV ,2000
- Peroxisome proliferator-activated receptor γ1 (PPARγ1) expresses in rat mesangial cells and PPARγ agonists modulate its differentiationBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2000
- PPAR‐γ‐Mediated Regulation of Normal and Malignant B Lineage CellsAnnals of the New York Academy of Sciences, 2000
- Activation of PPARα or γ Reduces Secretion of Matrix Metalloproteinase 9 but Not Interleukin 8 from Human Monocytic THP-1 CellsBiochemical and Biophysical Research Communications, 2000
- Inhibition of Adipogenesis by a COOH-Terminally Truncated Mutant of PPARγ2 in 3T3-L1 CellsBiochemical and Biophysical Research Communications, 1999
- Peroxisome proliferator-activated receptor-γ: a versatile metabolic regulatorAnnals of Medicine, 1999
- PPARγ3 mRNA: a distinct PPARγ mRNA subtype transcribed from an independent promoterFEBS Letters, 1998
- Inhibition of Adipogenesis Through MAP Kinase-Mediated Phosphorylation of PPARγScience, 1996